Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase two clinical study of the HLX43 for injection in mainland China, excluding the Hong Kong, Macau, and Taiwan regions, a Monday Hong Kong bourse filing said.
The injection is an antibody-drug conjugate and targets PD-L1 with a novel DNA topoisomerase I inhibitor.
The drug is being tested for the treatment of recurrent/metastatic esophageal squamous cell carcinoma, the cancer that forms in the thin, flat cells lining the inside of the esophagus.
The company plans to further the clinical trials for the treatment of potential indications such as cervical cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。